Changes to the Roche Corporate Executive Committee
Basel, 15 December 2011
Roche today announced that Sophie Kornowski-Bonnet, currently General Manager of Roche Pharma in France, has been appointed Head of Roche Partnering. Sophie Kornowski-Bonnet will assume her new role on February 1, 2012, and concurrently will join Roche’s enlarged Corporate Executive Committee, reporting to Severin Schwan, CEO of the Roche Group. She will relocate to Group headquarters in Basel, Switzerland and succeed Dan Zabrowski, who will take over the position as Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany, as of February 1, 2012. Dan Zabrowski will be a member of the Diagnostics leadership team and report to Daniel O’Day, COO Roche Diagnostics.
Commenting on the two appointments, Severin Schwan said: “Sophie Kornowski-Bonnet has an in-depth understanding of the healthcare industry. By running our French Pharma affiliate for the last five years Sophie has made tremendous contributions not only to the business but also to the development of a strong R&D hub in France. Assuming her new role as Head of Roche Partnering she can build on the great achievements Dan Zabrowski has made for the Partnering organization.” Schwan further: “As Head of Applied Science Dan will be key for driving this strategically important business with our customers in academia, biotech and pharmaceutical industries.”
Kornowski-Bonnet was born in Paris, earned a Doctorate in Pharmacy from the University Paris V in 1986 and an MBA in Marketing and Finance from the University of Chicago in 1989. Before joining Roche in 2007 she assumed various management roles in other international pharma companies.
Zabrowski, who is an American citizen, earned a PhD in Organic chemistry at the University of Indiana in 1987. In 1993 he joined Syntex, which was acquired by Roche in 1994. During his career at Syntex and Roche he has held a number of management positions in Pharma Development.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.